Eli Lilly Q3 Earnings: Mounjaro Hits $10.7B, Jardiance Jumps 64.5%
Seeking Alpha · October 29, 2026
Key takeaways
- Mounjaro generated $10.7 billion for Eli Lilly, underscoring continued strong demand for GLP-1 weight-loss and diabetes treatments.
- Jardiance sales grew 64.5% year-over-year to $1.58 billion, showing Lilly's legacy diabetes/heart-failure drug still has significant growth room.
- The results highlight Lilly's dual strength: a fast-growing new blockbuster plus an accelerating established portfolio.
The Numbers Eli Lilly just dropped its Q3 figures, and the headline stats are hard to ignore: Mounjaro, its blockbuster diabetes and weight-loss drug, pulled in $10.7 billion, while Jardiance — Lilly's diabetes and heart-failure treatment — jumped 64.5% year-over-year to $1.58 billion. For a company that's become the poster child of the GLP-1 boom, these numbers confirm the growth story isn't slowing down.
Why Mounjaro Keeps Climbing Mounjaro's trajectory has been one of the most-watched storylines in pharma over the past two years. Demand for GLP-1 drugs — originally developed for type 2 diabetes but now widely used for weight management — has outpaced supply in many markets. Lilly has been racing to expand manufacturing capacity to keep up, and the $10.7 billion figure suggests that investment is paying off. It also reinforces Lilly's position as a direct rival to Novo Nordisk's Ozempic and Wegovy in the increasingly crowded (and increasingly profitable) weight-loss drug race.
Jardiance's Quiet Surge While Mounjaro grabs the headlines, Jardiance's 64.5% jump is arguably just as notable. The drug, which treats type 2 diabetes, heart failure, and chronic kidney disease, has benefited from expanded approvals and growing physician confidence in its cardiovascular benefits. A nearly two-thirds year-over-year increase signals that Lilly's older portfolio isn't just coasting on legacy prescriptions — it's actively gaining market share.
What This Means for Lilly's Bigger Picture Together, these two drugs paint a picture of a company firing on multiple cylinders. Mounjaro represents the future-growth bet on metabolic health, while Jardiance shows that Lilly's established cardiometabolic franchise still has real room to run. For a pharma giant, having both a hot new product and a surging legacy drug is the kind of balance that tends to make Wall Street analysts happy.
What to Watch Next Investors will be watching whether Lilly can sustain manufacturing scale-up for Mounjaro without supply hiccups, and whether competitors — especially Novo Nordisk — respond with pricing or new formulations. On the Jardiance side, continued label expansions or new clinical data could keep that momentum going. Either way, Eli Lilly's Q3 results reinforce why it's currently one of the most closely tracked names in the healthcare sector.
Why it matters
Eli Lilly's earnings are a bellwether for the broader GLP-1 and diabetes-drug market, affecting everything from insurance coverage debates to competitor stock moves. If you follow healthcare investing or just want to understand why weight-loss drugs keep making headlines, these numbers are a key data point.
Want deals on what you love?
Val finds local offers matched to your interests — free to start.
Meet Val